Cardiology Department, Via Montaione 20 00139, Policlinico Casilino, Rome, Italy.
Europace. 2010 Dec;12(12):1707-12. doi: 10.1093/europace/euq327. Epub 2010 Sep 10.
Supraventricular tachycardia may trigger atrial fibrillation (AF). The aim of the study was to evaluate the prevalence of supraventricular tachycardia (SVT) inducibility in patients referred for AF ablation and to evaluate the effects of SVT ablation on AF recurrences.
Two hundred and fifty-seven patients (185 males; mean age: 53.4 ± 14.6 years) referred for AF ablation were studied. In all patients only AF relapses had been documented in the clinical history. Twenty-six patients (10.1%; mean age: 43.4 ± 13.3 years; 17 males) had inducible SVT during electrophysiological study and underwent an ablation targeted only at SVT suppression. Ablation was successful in all 26 patients. The ablative procedures are: 12 slow-pathway ablations for atrioventricular nodal re-entrant tachycardia; 9 concealed accessory pathway ablations for atrioventricular re-entrant tachycardia; and 5 focal ectopic atrial tachycardia ablations. No recurrences of SVT were observed during the follow-up (21 ± 11 months). Two patients (7.7%) showed recurrence of at least one episode of AF. Patients with inducible SVT had less structural heart disease and were younger than those without inducible SVT (interventricular septum thickness: 8.4 ± 1.6 vs. 11.0 ± 1.4 mm, P < 0.01; left atrial diameter: 37.0 ± 3.0 vs. 44.0 ± 2.2 mm, P < 0.01; age: 43.4 ± 13.3 vs. 57.3 ± 11.2 years, P < 0.01). Prevalence of paroxysmal AF was higher in patients with inducible SVT when compared with those with only AF (84.6 vs. 24.6%, P < 0.01).
A significant proportion of candidates to AF ablation are inducible for a SVT. SVT ablation showed a preventive effect on AF recurrences. Those patients should be selected for simpler ablation procedures tailored only on the triggering arrhythmia suppression.
室上性心动过速(SVT)可引发心房颤动(AF)。本研究旨在评估因 AF 消融而就诊的患者中 SVT 可诱发性的发生率,并评估 SVT 消融对 AF 复发的影响。
共研究了 257 名患者(185 名男性;平均年龄:53.4±14.6 岁),这些患者均有 AF 消融病史。在所有患者中,仅在临床病史中记录到 AF 复发。26 名患者(10.1%;平均年龄:43.4±13.3 岁;17 名男性)在电生理研究中可诱发出 SVT,并接受了仅针对 SVT 抑制的消融治疗。26 名患者的消融均成功。消融程序包括:12 例房室结折返性心动过速的慢径消融术;9 例房室折返性心动过速的隐匿性旁路消融术;以及 5 例局灶性房性心动过速消融术。在随访期间(21±11 个月),未观察到 SVT 复发。2 名患者(7.7%)出现至少一次 AF 复发。可诱发出 SVT 的患者的结构性心脏病较少,且年龄小于不能诱发出 SVT 的患者(室间隔厚度:8.4±1.6 与 11.0±1.4mm,P<0.01;左心房直径:37.0±3.0 与 44.0±2.2mm,P<0.01;年龄:43.4±13.3 与 57.3±11.2 岁,P<0.01)。与仅发生 AF 的患者相比,可诱发出 SVT 的患者阵发性 AF 的发生率更高(84.6%比 24.6%,P<0.01)。
相当一部分接受 AF 消融的患者可诱发出 SVT。SVT 消融对 AF 复发有预防作用。这些患者应选择仅针对触发心律失常抑制的更简单消融程序。